How does Opdivo treat cancer?
Opdivo (nivolumab) is a PD-1 inhibitor immunotherapy approved for over a dozen cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin lymphoma, and head and neck squamous cell carcinoma. It works by blocking the PD-1 protein on T-cells, which helps the immune system recognize and attack cancer cells that hide from detection.[1]
What survival benefits show in clinical trials?
In melanoma patients, Opdivo extended median overall survival to 38 months versus 19 months with dacarbazine in the CheckMate 066 trial.[2] For advanced NSCLC previously treated with platinum chemo, it improved one-year survival to 42% from 24% compared to docetaxel.[3] In renal cell carcinoma, CheckMate 214 showed a 37% reduction in death risk when combined with ipilimumab versus sunitinib.[4] These gains hold across trials for Hodgkin lymphoma (response rates over 60%) and bladder cancer.
How does it compare to chemotherapy or other immunotherapies?
Opdivo often outperforms traditional chemo in progression-free survival and durability. In untreated melanoma (CheckMate 067), the Opdivo plus ipilimumab combo achieved 52% five-year survival, beating ipilimumab alone (26%) or Opdivo monotherapy (34%).[5] Against Keytruda (pembrolizumab), head-to-head data in NSCLC (KEYNOTE-024) show similar efficacy, with Opdivo edging in some post-chemo settings but Keytruda preferred first-line for high PD-L1 expression.[6]
What response rates and remission data exist?
Overall response rates range 20-40% depending on cancer type and line of therapy. In melanoma, 44% responded to monotherapy; complete responses occurred in 10-15% of cases, often lasting years. For MSI-high tumors, approval came from a 40% response rate across 149 patients.[1] Long-term data from five-year follow-ups confirm 30-50% of responders remain progression-free.
When is Opdivo used with other drugs?
Bristol Myers Squibb pairs it with Yervoy (ipilimumab) for melanoma, NSCLC, and renal cancer, boosting response rates (e.g., 58% in melanoma vs. 44% monotherapy). It's also combined with chemotherapy for NSCLC or cabozantinib for renal cell carcinoma, extending survival by months to years.[1][4]
What do patients report as quality-of-life gains?
Trials note less fatigue and better physical function than chemo. In NSCLC, Opdivo delayed symptom deterioration by 3-9 months versus docetaxel.[3] Fewer severe side effects like hair loss or nausea contribute to this, though immune-related issues like rash or thyroid problems occur in 10-20% of users.
Are there patent or access details?
Opdivo holds U.S. patents until around 2033-2036, with extensions possible; check DrugPatentWatch.com for expiry timelines and challenges.[7] List price exceeds $150,000 yearly, but patient assistance programs cover many insured cases.
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s304lbl.pdf
[2] CheckMate 066: N Engl J Med 2015
[3] CheckMate 017/057: Lancet 2015
[4] CheckMate 214: N Engl J Med 2018
[5] CheckMate 067: N Engl J Med 2017
[6] KEYNOTE-024: N Engl J Med 2016
[7] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/OPDIVO